39% |
Stage #1: N,N-diethyl-4-bromobenzenesulfonamide With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 1h;
Stage #2: With N-sulfinyltriphenylmethylamine In tetrahydrofuran; hexane at -78 - 0℃; for 0.5h;
Stage #3: (R)-ethyl nipecotate Further stages; |
I Ethyl (3R)-1-(4-(N,N-diethylsulfamoyl)phenylsulfonimidoyl)piperidine-3-carboxylate (DX2-225).
To a solution of 2a (100 mg, 0.34 mmol) in THF (4 mL) was added nBuLi (0.14 mL, 0.34 mmol, 2.5 M in hexane) dropwise and the mixture was stirred at the same temperature for 1h. N- Sulfinyltriphenylmethylamine (104 mg, 0.34 mmol) was then added as a THF solution dropwise and the mixture was stirred at the same temperature for 25 min before warmed to 0°C in an ice bath. After stirred for 5 min, tBuOCl (39 mg, 0.36 mmol) was added in a darkened hood with aluminum foil covering the flask and stirred for 25 min. Then ethyl (R)-piperidine-3-carboxylate (80 mg, 0.51 mmol) and Et3N (34 mg, 0.34 mmol) was added, and the mixture was stirred at room temperature overnight and quenched with MsOH (326 mg, 3.40 mmol), diluted with DCM, washed with sat.aq. NaHCO3, brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified with preparative HPLC to give DX2-225 as a white solid (57 mg, 39%). 1H NMR (300 MHz, CDCl3) δ 8.20 (dd, J = 6.0, 3.4 Hz, 1H), 8.05 (dd, J = 5.9, 3.5 Hz, 1H), 7.68 (dd, J = 5.9, 3.4 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.95 (d, J = 13.9 Hz, 1H), 3.83 (d, J = 13.4 Hz, 1H), 3.53-3.34 (m, 4H), 2.98 (dd, J = 13.0, 10.6 Hz, 1H), 2.91-2.80 (m, 1H), 2.72-2.61 (m, 1H), 2.22-2.03 (m, 1H), 1.85-1.47 (m, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.1 Hz, 6H). LC-MS (ESI) m/z 432.0 [M + H]+. |
39% |
Stage #1: N,N-diethyl-4-bromobenzenesulfonamide With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 1h;
Stage #2: With N-sulfinyltriphenylmethylamine In tetrahydrofuran; hexane at -78 - 0℃; for 0.5h;
Stage #3: (R)-ethyl nipecotate Further stages; |
I Ethyl (3R)-1-(4-(N,N-diethylsulfamoyl)phenylsulfonimidoyl)piperidine-3-carboxylate (DX2-225).
To a solution of 2a (100 mg, 0.34 mmol) in THF (4 mL) was added nBuLi (0.14 mL, 0.34 mmol, 2.5 M in hexane) dropwise and the mixture was stirred at the same temperature for 1h. N- Sulfinyltriphenylmethylamine (104 mg, 0.34 mmol) was then added as a THF solution dropwise and the mixture was stirred at the same temperature for 25 min before warmed to 0°C in an ice bath. After stirred for 5 min, tBuOCl (39 mg, 0.36 mmol) was added in a darkened hood with aluminum foil covering the flask and stirred for 25 min. Then ethyl (R)-piperidine-3-carboxylate (80 mg, 0.51 mmol) and Et3N (34 mg, 0.34 mmol) was added, and the mixture was stirred at room temperature overnight and quenched with MsOH (326 mg, 3.40 mmol), diluted with DCM, washed with sat.aq. NaHCO3, brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified with preparative HPLC to give DX2-225 as a white solid (57 mg, 39%). 1H NMR (300 MHz, CDCl3) δ 8.20 (dd, J = 6.0, 3.4 Hz, 1H), 8.05 (dd, J = 5.9, 3.5 Hz, 1H), 7.68 (dd, J = 5.9, 3.4 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.95 (d, J = 13.9 Hz, 1H), 3.83 (d, J = 13.4 Hz, 1H), 3.53-3.34 (m, 4H), 2.98 (dd, J = 13.0, 10.6 Hz, 1H), 2.91-2.80 (m, 1H), 2.72-2.61 (m, 1H), 2.22-2.03 (m, 1H), 1.85-1.47 (m, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.1 Hz, 6H). LC-MS (ESI) m/z 432.0 [M + H]+. |
39% |
Stage #1: N,N-diethyl-4-bromobenzenesulfonamide With n-butyllithium; hypochlorous acid tert-butyl ester; N-sulfinyltriphenylmethylamine In tetrahydrofuran at -78 - 0℃; for 1.83333h;
Stage #2: (R)-ethyl nipecotate With triethylamine In tetrahydrofuran at 20℃; |
|